When we last checked in on Dan Loeb’s Third Point it was mid 2017 and the fund was cruising while also singing the praises of Baxter International (BAX). Unfortunately, 2018 was a rough year for the firm and performance, at -11.3%, lagged the overall S&P 500. Market Folly shares the fund’s recent Q4 mea culpa letter which offers… Read More »
Who says persistence doesn’t pay off? Months after having a buyout offer rejected and weeks after reports of its continued interest in a deal, Shire (SHPG) has reportedly gotten recent Baxter International (BAX) spinoff Baxalta (BXLT) to sit down at the table for a little M&A pow-wow. Apparently the two are making progress on a deal which would include… Read More »
Some people just won’t take no for an answer. According to Reuters, Shire (SHPG) is getting ready to unveil a higher bid for recent spinoff Baxalta (BXLT), after its unsolicited $30b offer was rejected earlier this year. At the time of the initial offer, the orphan disease focused company had been independent for about roughly two minutes and argued… Read More »
How quickly things change. Last week, word was Baxter (BAX) spinoff Baxalta (BXLT) was in talks to acquire oncology focused Ariad Pharmaceuticals (ARIA). The rumored $2b price tag sent Ariad shares soaring, but alas, today shares are crashing on word the deal has been called off. According to Bloomberg, there were a couple of pretty big issues that emerged:… Read More »